Hayward, CA, United States of America

Eric Hans Vermaas

This inventor holds 17 USPTO granted patents and 9 published patent applications, plus 3 CIPO patents and 12 EPO patents, primarily in Nucleic Acid Sequencing. Top assignees: Illumina Corporation, Illumina Cambridge Limited. Active years: 2012-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Eric Hans Vermaas. Retrieved from https://idiyas.com/inventor/eric-hans-vermaas

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 17 

% Patents Active = 88.2

 

 

Average Co-Inventor Count = 4.3

ph-index = 4

Forward Citations = 237(Granted Patents)


Location History:

  • Walden, GB (2012)
  • Hayward, CA (US) (2012 - 2015)
  • San Diego, CA (US) (2016 - 2023)

Company Filing History:


Years Active: 2012-2026

Loading Chart...
Loading Chart...
Loading Chart...
Areas of Expertise:
Nucleic Acid Libraries
Sample Identification
Multiplex Sequencing
Short Adapters
Index Sequences
Liquid Separation
Sequencing Apparatus
Polynucleotide Templates
Sequence by Synthesis
Integrated Systems
17 patents (USPTO):Explore Patents

Title: Innovations of Eric Hans Vermaas: A Pioneer in Nucleotide Indexing

Introduction

Eric Hans Vermaas, a prominent inventor based in Hayward, California, has made significant contributions to the field of biotechnology through his innovative inventions. With a prolific portfolio comprising 15 patents, Vermaas has focused primarily on advancements in the indexing of polynucleotide samples. His work not only enhances the efficiency of genetic sequencing but also plays a vital role in various applications within the biotechnology sector.

Latest Patents

Among Vermaas's latest patents are groundbreaking inventions dealing with index oligonucleotides. One notable patent is titled "Universal Short Adapters for Indexing of Polynucleotide Samples." This innovation involves the design of index oligonucleotides that help identify the sources of nucleic acid samples. The invention provides methods, apparatus, systems, and computer program products that facilitate the identification and creation of these index oligonucleotides. Central to the invention is the inclusion of a set of index sequences, along with a Hamming distance metric that establishes criteria for any two index sequences within that set. These advancements are crucial in determining sequences of interest using the developed index oligonucleotides.

Another significant patent focuses on "Optimal Index Sequences for Multiplex Massively Parallel Sequencing." Similar to the previous invention, this patent also revolves around index oligonucleotides, providing methods and systems for their identification and creation. The merging of innovative concepts in both patents showcases Vermaas's commitment to enhancing the accuracy and efficacy of nucleic acid sequencing.

Career Highlights

Throughout his career, Eric Hans Vermaas has been associated with top-tier biotechnology firms, including Illumina Corporation and Illumina Cambridge Limited. His tenure at these institutions has facilitated groundbreaking research and development in genomics, enabling advancements in sequencing technologies that have wide-reaching implications in healthcare and research.

Collaborations

Vermaas's innovative journey is supported by collaborations with fellow professionals in the field. Notably, he has worked alongside esteemed colleagues such as Colin Lloyd Barnes and Graham John Worsley. These collaborations have fostered an environment of shared knowledge and expertise, further propelling his inventive pursuits.

Conclusion

Eric Hans Vermaas stands out as an influential figure in the realm of biotechnology. His inventions, particularly in the field of polynucleotide indexing, reflect his dedication to advancing genetic science. With a robust patent portfolio and a history of collaboration with industry leaders, Vermaas continues to inspire future innovations in the biotechnology landscape.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…